179 related articles for article (PubMed ID: 25982179)
1. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.
Emadi A; Sadowska M; Carter-Cooper B; Bhatnagar V; van der Merwe I; Levis MJ; Sausville EA; Lapidus RG
Leuk Res; 2015 Jul; 39(7):719-29. PubMed ID: 25982179
[TBL] [Abstract][Full Text] [Related]
2. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
Estañ MC; Calviño E; Calvo S; Guillén-Guío B; Boyano-Adánez Mdel C; de Blas E; Rial E; Aller P
PLoS One; 2014; 9(12):e115250. PubMed ID: 25506699
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
Wang LN; Tang YL; Zhang YC; Zhang ZH; Liu XJ; Ke ZY; Li Y; Tan HZ; Huang LB; Luo XQ
Leuk Lymphoma; 2017 Oct; 58(10):2426-2438. PubMed ID: 28276286
[TBL] [Abstract][Full Text] [Related]
5. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.
Takahashi S; Harigae H; Yokoyama H; Ishikawa I; Abe S; Imaizumi M; Sasaki T; Kaku M
Int J Hematol; 2006 Oct; 84(3):256-61. PubMed ID: 17050201
[TBL] [Abstract][Full Text] [Related]
7. [Synergistic lethal effect of combined treatment of arsenic trioxide and aclacinomycin on human acute myeloid leukemia cell line KG-1a].
Ye YB; Xu XJ; Chen YH; Zhang MW; Qiu DF; Guo ZW; He HQ
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):256-262. PubMed ID: 28550664
[No Abstract] [Full Text] [Related]
8. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
Bonati A; Rizzoli V; Lunghi P
Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
10. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species.
Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A
Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499
[TBL] [Abstract][Full Text] [Related]
11. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells.
Sun RC; Board PG; Blackburn AC
Mol Cancer; 2011 Nov; 10():142. PubMed ID: 22093145
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway.
Chen L; Han F; Qu H; Yan H; Ren L; Yang S
Pharmazie; 2013 Feb; 68(2):117-23. PubMed ID: 23469683
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation.
Dembitz V; Lalic H; Ostojic A; Vrhovac R; Banfic H; Visnjic D
Int J Hematol; 2015 Jul; 102(1):12-24. PubMed ID: 25758096
[TBL] [Abstract][Full Text] [Related]
14. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
Aldoss I; Mark L; Vrona J; Ramezani L; Weitz I; Mohrbacher AM; Douer D
Ann Hematol; 2014 Nov; 93(11):1839-43. PubMed ID: 24906216
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with arsenic trioxide for hematological malignancies.
Takahashi S
Anticancer Agents Med Chem; 2010 Jul; 10(6):504-10. PubMed ID: 20812901
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Dihydroartemisinin and Arsenic Trioxide on Apoptosis of Acute Myeloid Leukemia Cells].
Sun WD; Wang X; Wang Y; Tong XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1337-1342. PubMed ID: 36208232
[TBL] [Abstract][Full Text] [Related]
17. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
Chau D; Ng K; Chan TS; Cheng YY; Fong B; Tam S; Kwong YL; Tse E
J Hematol Oncol; 2015 May; 8():46. PubMed ID: 25953102
[TBL] [Abstract][Full Text] [Related]
18. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
Bachleitner-Hofmann T; Gisslinger B; Grumbeck E; Gisslinger H
Br J Haematol; 2001 Mar; 112(3):783-6. PubMed ID: 11260084
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Parmar S; Rundhaugen LM; Boehlke L; Riley M; Nabhan C; Raji A; Frater JL; Tallman MS
Leuk Res; 2004 Sep; 28(9):909-19. PubMed ID: 15234567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
